Trial Profile
A Prospective Randomized Open, Blinded End-point controlled study evaluating the resolution and recurrence of left ventricular thrombus with different anti coagulation strategies
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Feb 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Low molecular weight heparins; Warfarin
- Indications Thrombosis
- Focus Therapeutic Use
- Acronyms RELEVENT
- 11 Feb 2021 Planned number of patients changed from 500 to 50.
- 11 Feb 2021 Status changed from not yet recruiting to recruiting.
- 02 Aug 2018 New trial record